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Abstract
The natural product nobiletin is a small molecule, widely studied with regard to its therapeu-
tic effects, including in cancer cell lines and tumors. Recently, nobiletin has also been
shown to affect circadian rhythms via their enhancement, resulting in protection against met-
abolic syndrome. We hypothesized that nobiletin’s anti-oncogenic effects, such as preven-
tion of cell migration and formation of anchorage independent colonies, are correspondingly
accompanied by modulation of circadian rhythms. Concurrently, we wished to determine
whether the circadian and anti-oncogenic effects of nobiletin differed across cancer cell
lines. In this study, we assessed nobiletin’s circadian and therapeutic characteristics to
ascertain whether these effects depend on cell line, which here also varied in terms of base-
line circadian rhythmicity. Three cell culture models where nobiletin’s effects on cell prolifer-
ation and migration have been studied previously were evaluated: U2OS (bone
osteosarcoma), which possesses robust circadian rhythms; MCF7 (breast adenocarci-
noma), which has weak circadian rhythms; and MDA-MB-231 (breast adenocarcinoma),
which is arrhythmic. We found that circadian, migration, and proliferative effects following
nobiletin treatment were subtle in the U2OS and MCF7 cells. On the other hand, changes
were clear in MDA-MB-231s, where nobiletin rescued rhythmicity and substantially reduced
oncogenic features, specifically two-dimensional cell motility and anchorage-independent
growth. Based on these results and those previously described, we posit that the effects of
nobiletin are indeed cell-type dependent, and that a positive correlation may exist between
nobiletin’s circadian and therapeutic effects.
Introduction
Nobiletin is a polymethoxylated flavone present in the peels of citrus fruits [1]. It has been
reported to yield therapeutic effects in a variety of disease models, including those of neurolog-
ical, inflammatory, cardiac, and metabolic diseases, in addition to cancer cell lines and tumors.
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Recently, it has also been shown to affect circadian oscillations [2,3]. We are interested in con-
comitant studies of nobiletin’s therapeutic and circadian effects. Previous studies have shown
that nobiletin can improve memory in Alzheimer’s [4] and motor deficits in Parkinson’s dis-
ease models [5], and can result in anti-depressant-like effects (i.e. reduced immobility times in
forced swimming and tail suspension tests in mice) [6]. It can also ameliorate adiposity, hyper-
lipidemia, hyperglycemia, and insulin resistance [7], attenuate lipid accumulation [8], protect
against metabolic syndrome [2], reduce excessive inflammatory responses and restore epithe-
lial barrier function in colitis [9], and protect against acute pancreatitis [10]. For heart diseases,
nobiletin results in neuroprotection of cerebral ischemia-reperfusion [11], lowers serum low-
density lipoprotein (LDL)/very low-density lipoprotein (VLDL) cholesterol [12], and has been
shown to ameliorate cardiac dysfunction [13]. In mouse models, nobiletin has been shown to
affect aging processes, including inhibition of bone resorption and maintenance of bone mass
[14]. On these accounts, nobiletin has the potential to serve as a therapeutic entity against
numerous conditions.
Treatment with nobiletin has resulted in anti-oncogenic effects in multiple cancer cell lines
and tumor types by affecting major pathways including protein kinase B (AKT), mitogen-acti-
vated protein kinase (MAPK), transforming growth factor beta-1 (TGF-β1)/SMAD3, extracel-
lular-signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK). In studies where it
was shown to affect the AKT pathway, nobiletin was found to decrease tumor viability, weight,
and volume in A2780/CP70 ovarian cancer xenograft models [15]. It also reduced cell adhe-
sion, invasion, and migration in the highly metastatic AGS gastric adenocarcinoma cell line
[16], suppressed viability of PC-3 and DU-145 prostate cancer cell lines [17], and inhibited
ACHN and Caki-2 renal carcinoma cell proliferation by cell cycle arrest in G0/G1 phase [18].
Also, nobiletin reduced proliferation and induced apoptosis in HL-60 human acute myeloid
leukemia cells [19], diminished proliferation and migration in U87 glioma cells [20], and
decreased cell proliferation in the low tumor-grade MCF7 cell line via G1 cell cycle block [21].
It may induce apoptosis and inhibit cell migration via MAPK and/or MAPK/AKT related
pathways [22,23]. Similar anti-proliferative effects have been observed in high tumor grade
MDA-MB-231 [23] and MDA-MB-468 human breast cancer cells following treatment with
nobiletin [24]. Nobiletin has also been shown to inhibit growth of metastatic nodules in the
lungs of mice via the TGF-β1/SMAD3 pathway [25] and decrease cell migration, angiogenesis,
tumor formation, and progression in the bone osteosarcoma cell line U2OS via ERK and JNK
pathways [26]. Taken together, nobiletin is effective against cell lines and tumors representing
various cancer types, and exerts its effects via various pathways.
While identification of small molecules that can modulate circadian rhythms has garnered
significant interest [27], it has recently been shown that many existing therapeutic compounds
also affect circadian rhythms [28]. In a similar fashion, nobiletin, which has been known for
decades to elicit various beneficial health effects, has only recently been shown to alter circa-
dian rhythms [2,3]. Circadian rhythms are 24-hour rhythmic activity cycles. At the molecular
level, they are regulated by circadian locomoter output cycles kaput (CLOCK), brain and mus-
cle ARNT-Like 1 (BMAL1), period (PER), and cryptochrome (CRY) proteins, which exist in a
negative feed-back loop [29]. CLOCK and BMAL1 are positive components that result in gene
expression, including of the negative regulators PER1, PER2, PER3, CRY1, and CRY2. Nobile-
tin has been shown to activate a critical component of a secondary loop, retinoic acid-related
orphan receptor (ROR) [2], which binds to the Bmal1 promoter, activating its transcription
[29]. While other targets may exist, and at least two have been computationally predicted
[23,30], they have yet to be determined. Two prior studies have assessed nobiletin’s circadian
effects. In the first, mouse embryonic fibroblasts (MEFs) from heterozygous Clock knockout
mice and mouse ear fibroblasts from PER2::LucSV reporter mice showed increased PER2:Luc
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amplitudes, which were confirmed to be the result of increased ROR activity [2]. In a second
study, nobiletin similarly increased amplitudes but also lengthened the periods of PER2::Luc in
MEFs, while inducing phase delays in liver slices from PER2::Luc knock-in mice [3]. However,
despite nobiletin’s therapeutic applications, to our knowledge, its simultaneous effects on cir-
cadian rhythms have been addressed only in a single study [2]. Therefore, here we assess nobi-
letin’s circadian and therapeutic effects in parallel, under the same treatment conditions and
models.
Given the substantial evidence of nobiletin’s efficacy in reducing cell migration and prolif-
eration in cancer cell lines and tumors, we considered it important to evaluate its circadian
effects in these systems. In this study, we used three cancer cell lines, each of which nobiletin
has shown activity in: U2OS, MCF7, and MDA-MB-231. Based on previous work, U2OS is a
cell line with robust circadian rhythms [31], the low-grade breast cancer cell line MCF7 has
low amplitude oscillations, and the high tumor grade breast cancer cell line MDA-MB-231 is
arrhythmic [32]. We were particularly interested in determining whether the extent of oscilla-
tion robustness and nobiletin-influenced circadian changes could be correlated with anti-
oncogenic effects. To assess this, we dosed the cells with two concentrations of nobiletin and
evaluated how circadian rhythms are affected using real-time luminometry. We evaluated the
oncogenic features of cell migration and anchorage-independent clonal expansion using
wound healing and colony formation assays, respectively. Upon nobiletin treatment, we found
subtle circadian alterations in U2OS and MCF7 cells, but strikingly observed enhanced rhyth-
micity in otherwise arrhythmic MDA-MB-231 cells [32]. Under the same conditions, onco-
genic features in U2OS cells were disparately affected, with motility reduced, but increased
colony areas observed. In MCF7 cells, cell migration was not altered, but at the highest concen-
tration, colony areas decreased. The most significant changes were observed in nobiletin




U2OS [33] cells were obtained from Prof. Patricia Wadsworth (Biology, UMass Amherst),
MCF7 [34] cells were obtained from Prof. D. Joseph Jerry (Veterinary and Animal Sciences,
UMass Amherst), and MDA-MB-231 [35] cells were obtained from Prof. Shelly Peyton
(Chemical Engineering, UMass Amherst). MCF7 cells were characterized for expression of
estrogen receptor and its signaling. MDA-MB-231s were evaluated for karyotype and subtype
confirmation via RNAseq prior to transfer. Both cell lines were tested for mycoplasma via PCR
detection. U2OS cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM;
Gibco), with 10% Fetal Bovine Serum (FBS; Corning), 1% L-Glutamine (L-glut; Gibco), 1%
penicillin-streptomycin (Gibco), 1% Non-Essential Amino Acids (HyClone), and 1% Sodium
Pyruvate (Gibco) [36]. MCF7 and MDA-MB-231 cells were maintained in DMEM (Gibco),
supplemented with 10% FBS (Corning), 1% penicillin-streptomycin (Gibco), and 1% L-glut
(Gibco) [32]. All cells were incubated at 37˚C under 5% CO2 atmosphere, unless otherwise
noted.
Lentiviral transductions
The generation of Bmal1:luc and Per2:luc plasmids [37] and their subsequent stable transfec-
tion into U2OS [36], MCF7, and MDA-MB-231 [32] cells have been described previously.
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Nobiletin treatments
Nobiletin (Acros Organics, catalog number AC463522500, lot number A0390078) was pre-
pared in 100% dimethyl-sulfoxide (DMSO; Sigma-Aldrich) at a concentration of 191 mM and
stored at -20˚C in single use aliquots. When dosing cells, the nobiletin stock was serially
diluted in DMSO to achieve the desired concentration while maintaining a final, constant
DMSO concentration of 0.2% (including vehicle controls) in media. Media, prepared accord-
ing to experiment type, containing DMSO/nobiletin was added to synchronized cells
(described below) and left in the dish for the duration of each experiment.
Cell synchronization
Cells were seeded in 35 mm culture dishes in 2 mL at a density of 2 x 105 cells/mL and incu-
bated for 2–4 days. For luminometry, synchronization was performed when U2OS and
MDA-MB-231 cells were confluent, while MCF7 cells were approximately 90% confluent. For
RT-PCR and cell viability experiments all cells were confluent at the initiation of the experi-
ments. Synchronization methods differed by cell line, and were based on previously reported
protocols [32,38–43] that were optimized in our laboratory to obtain the best oscillations pos-
sible. U2OS growth media was then aspirated and 100 nM dexamethasone-containing culture
media added for 2 h to synchronize the cells as in prior studies [28,44,45]. U2OS cells were not
starved before synchronization. For MCF7, cells were washed with phosphate buffered saline
(PBS) and synchronized by subjecting them to starvation conditions (DMEM with 1% L-glut)
for 18 h followed by either treatment with 100 nM dexamethasone-containing DMEM with
1% L-glut (for luminometry) or 2 h serum shock in 1:1 FBS and DMEM with 1% L-glut (for
wound healing and colony formation assays). The concentration and duration of dexametha-
sone treatment used here are not expected to synchronize the cell cycle, as shown previously
[46]. For MDA-MB-231, cells were washed with PBS and synchronized via 18 h starvation in
DMEM with 1% L-glut followed by 2 h serum shock in 1:1 FBS and DMEM with 1% L-glut.
Cells were then treated according to experiment-specific procedures, described below.
Cell viability assay
U2OS, MCF7, and MDA-MB-231 cells were seeded in a 24 well plate in 0.5 mL at a density of
2 x 105 cells/mL, and grown to confluence. Depending on sample, cells were not treated, or
treated with DMSO vehicle (to 0.2%), 5 μM nobiletin or 50 μM nobiletin (both with 0.2%
DMSO). Cells were incubated for 24 h at 37˚C in 5% CO2. Then the culture media was
replaced with 10% Alamar blue reagent (Invitrogen) and incubated for 1 h under the same
conditions. The Alamar blue reagent was then transferred to a black 96 well plate (Costar), and
samples excited at 540 nm and emission detected at 590 nm using a Synergy H1 microplate
reader.
RNA isolation, cDNA conversion, and RT-PCR
U2OS, MCF7, and MDA-MB-231 cells were seeded in a 24 well plate in 0.5 mL at a density of
2 x 105 cells/mL and grown for 2–4 days. Depending on sample, cells were not treated, or
treated with DMSO vehicle (to 0.2%), 5 μM nobiletin or 50 μM nobiletin (both with 0.2%
DMSO). Cells were then incubated for 24 h. After, the RNA was harvested as described previ-
ously [32]. Briefly, RNA was harvested from cells using a PureLink RNA Mini Kit (Ambion)
according to the manufacturer’s instructions. RNA was reverse transcribed to cDNA using
50 μM random hexamers, 10 mM dNTPs, 40 U/μL RNaseOut, and 200 U/μL SuperScript IV
Reverse Transcriptase, 100 mM DTT, and 5x SSIV buffer (Thermo Fisher Scientific). RT-PCR
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was performed in 96-well plates. Each reaction consisted of 100 ng cDNA, 10 μL iTaq universal
SYBR Green Supermix (Biorad), 4 μM of each forward and reverse primer (Integrated DNA
Technologies), and RNAse-free water to 20 μL. The primers used are GAPDH forward (5'-
CTT CTT TTG CGT CGC CAG CC-3’), reverse (5'- ATT CCG TTG ACT CCG ACC
TTC-3'); Bmal1 forward (5’- CTA CGC TAG AGG GCT TCC TG-3’), reverse (5’-
CTT TTC AGG CGG TCA GCT TC-3’); Per2 forward (5’- TGT CCC AGG TGG AGA
GTG GT-3’), reverse (5’- TGT CAC CGC AGT TCA AAC GAG-3’). The samples were
centrifuged and analyzed via CFX Connect real-time system (Biorad) using an initial denatur-
ation at 95˚C for 3 min, followed by 40 cycles of 95˚C denaturation for 10 s, and 60˚C anneal-
ing/extension for 30 s. Relative Bmal1 and Per2 expression were determined by comparing Ct
values of Bmal1 and Per2 to GAPDH (control) via 2ΔΔCt method [47]. Three biological repli-
cates and three technical replicates per biological replicate were analyzed for each condition.
Bioluminescence recording and analysis
Following synchronization as described above, media was replaced with bioluminescence
recording media. For U2OS cells, bioluminescence recording media was prepared by dissolv-
ing powdered DMEM (Sigma-Aldrich) in Millipore-purified water (18.2 MΩ.cm resistance) to
give a final concentration of 0.01125 g/mL. This solution was sterile filtered using a 0.2 μm fil-
ter (Thermo Fisher) and used to prepare recording media containing the following additives
(final concentrations are indicated here): 4mM sodium bicarbonate (Gibco), 5% FBS (Corn-
ing), 1% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; HyClone), 0.25% peni-
cillin-streptomycin (Gibco), and 150 μg/mL D-luciferin (Pierce). For MCF7 and MDA-MB-
231 cells, recording media was prepared by dissolving powdered DMEM (Sigma-Aldrich) in
Millipore water to give a final concentration of 0.0135 g/mL. This solution was sterile filtered
using a 0.2 μm filter (Thermo Fisher) and used to prepare recording media containing the fol-
lowing additives (final concentrations are indicated here): 1% sodium pyruvate (Thermo Sci-
entific), 5% FBS, 1% HEPES, 1% penicillin-streptomycin, and 150 μg/mL D-luciferin (Pierce).
Dishes were sealed with 40 mm sterile cover glass using silicone vacuum grease and subjected
to monitoring using a LumiCycle 32 System (Actimetrics) at 36.5˚C for 5–7 days.
Each bioluminescence recording was pre-processed to remove an initial 12 h transient and
spikes. Recordings from rhythmic cell lines (U2OS and MCF7) were then de-trended and cir-
cadian parameters estimated. Time-series were de-trended by removing the 24 h moving aver-
age (which excludes an additional 12 hours of data) and smoothed using the 3 h running
average method. Circadian amplitude, period, and damping rate of each time-series were esti-
mated with two approaches. The first was to fit the first three cycles (t = 24 h to t = 96 h) to a
damped cosine curve with a nonlinear least squares method, using R (www.r-project.org) code
adapted from Hirota et al [48]. The second approach was to identify the time and magnitude
of each phase marker (peak, trough, mean-crossing on the rise, mean-crossing on the fall) of
the first three cycles (custom Matlab script). Each phase marker was used to estimate a period
(e.g. average peak-to-peak measurements led to one estimate and trough-to-trough to a sec-
ond), providing four additional period estimates. The amplitude was estimated by adding the
magnitude of the first trough to the magnitude of the first peak. To capture damping, the ratio
of the amplitude of the second cycle to that of the first cycle was subtracted from unity.
Wound healing assay
U2OS, MCF7, and MDA-MB231 cells were seeded in 0.5 mL at a density of 2 x 105 cells/mL
(U2OS) and ~4 x 105 cells/mL (MCF7, MDA-MB-231), in 24-well plates and incubated until
100% confluence was reached (2–4 days). Cells were synchronized as described above.
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Wounds were generated using a 1 mL micropipette tip. Culture media was then removed, cells
were washed with PBS, and 500 μL of new culture media containing indicated treatments was
added into each well. Images were taken immediately following for the first time point (T = 0)
and then every 2 h for 24 h via Biotek Cytation 3 cell imaging multi-mode plate reader.
Wound closure (%) was determined by normalizing wound area quantified at each time point
via macros adapted from MRI wound healing tool (http://dev.mri.cnrs.fr/projects/imagej-
macros/wiki/Wound_Healing_Tool) to T = 0 via ImageJ.
Colony formation assay
Cells were suspended in agarose and incubated until colonies formed, similarly to a previously
described procedure [37]. Briefly, 3% 2-Hydroxyethyl Agarose (Sigma) was prepared and
stored in a water bath at 45˚C. Cell culture media at 37˚C was used to dilute agarose to 0.6%,
and 500 μL of the resulting solution was added to each well of a 24-well plate (Nuclon), which
was incubated at 4˚C until the agarose solidified to produce the first layer. The agarose solution
was also added to the suspended cells (U2OS: 1 x 104 cells/mL; MCF7 and MDA-MB-231 3.5 x
103 cells/mL) in warm culture media to 0.3%, followed by addition of nobiletin. 500 μL of the
drug-cell-agarose solution was dispensed per well and incubated at 4˚C for 30 min until the
second agarose layer solidified. Then plates were transferred and incubated at 37˚C under 5%
CO2. A feeder layer of 0.3% agarose in culture media containing nobiletin at designated con-
centrations (in 500 μL) was added to each well once every 7 days for 4 weeks. When imaging
colonies, 20% methanol (Fisher Scientific) was added to wells, and plates were incubated on a
shaker at rt for 1 h. Eight images were taken per well using a Biotek Citation 3 multi-mode cell
imaging reader. Each condition was performed in three biological replicates. Images were
stitched and colony numbers/sizes were analyzed using ImageJ software [49].
Statistical analysis
To determine whether each bioluminescence time-series was rhythmic, we applied a fast fou-
rier transform (FFT)-based statistical test designed for circadian bioluminescence recordings
[50]. The null hypothesis was that the time-series exhibits characteristics of Brownian motion,
meaning that the power spectrum is a linear function of the reciprocal of the frequency
squared. The null hypothesis was rejected if the circadian peak of the power spectral density is
above the regression line in log-log space (significance determined by a one-tailed Student’s t-
test). Before applying the test, an exponential (for results in main text) or a quadratic (for sup-
plementary results) trend was removed.
To compare circadian parameters between doses, a one-tailed randomization test for differ-
ence in means was used (http://www.lock5stat.com/StatKey/index.html). This test was chosen
because a t-test was inappropriate (as it requires that each sample size is either large or nor-
mally distributed). In our case, N = 12 for each condition and not all were normally distrib-
uted. For each cell line, the test was performed for pairs of doses (e.g. non-treated to 5 μM
nobiletin). The reference test statistic was the absolute value of difference in means between
the given circadian parameter (e.g. period) for the two doses. The null distribution was gener-
ated by creating 10,000 random permutations of the dose labels and computing the test statis-
tic for each permutation. The p-value was the fraction of statistics from the null distribution
that were larger than the reference statistic.
To compare wound closure between doses, a one-tailed randomization test for longitudinal
data was used [51]. It employs regression to test the null hypothesis that the dose did not affect
the shape of the best-fit curve. For our data, the null hypothesis was more specifically that fit-
ting a quadratic (with zero-intercept) to the data for both doses leads to a fit that is
PLOS ONE Circadian and anti-oncogenic effects of nobiletin
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indistinguishable from fits from data for each individual dose. The reference test statistic was
an F-statistic computed from the sum of the residuals for the pooled data in comparison to
that for a fit to data from one dose. The null distribution was generated by un-correlating and
shuffling the residuals and then computing the test statistic (see Storey et al, 2005 for more
details; the process was repeated 1,000 times) [51]. The p-value was the fraction of the statistics
from the null distribution that were smaller than the reference statistic. Multiple comparisons
were corrected according to the Bonferroni method.
Results
Nobiletin affects circadian oscillations of Per2:luc and Bmal1:luc in U2OS,
MCF7, and MDA-MB-231 cells in a cell-dependent manner
To assess the circadian effects of nobiletin in a detailed approach, we used luciferase-reporter
cells for Bmal1 and Per2 promoter activity previously generated in our lab [37]. Here, we
employed U2OS, MCF7, and MDA-MB-231 cell lines separately transfected with Bmal1:luc
and Per2:luc [32,36]. Prior to initiating luminometry experiments, we evaluated potential via-
bility effects of treatments to be used. The highest and lowest concentrations used in this study
were determined based on multiple factors, including those used in previous studies, results
from our viability assay (S1 Fig), and our desire to apply consistent nobiletin concentrations
across cell lines. For reference, the concentration required for 50% induction of CYP1 enzyme
activity in MCF7 cells is 44 μM [21]. IC50 values are not available for U2OS and MDA-MB-231
cells. Therefore, concentrations of 5 μM and 50 μM of nobiletin were used. While slightly
diminished viability (~80%) was observed for U2OS cells treated at the highest concentration,
none of the other cells or treatments resulted in significant changes (S1 Fig).
The same conditions were used to track circadian oscillations via reporter bioluminescence
using real-time luminometry for 6 days (Fig 1 and S2–S5 Figs). A total of N = 12 replicates per
condition per cell line/reporter was obtained, across three independent experiments, with
N = 4 each. Consistent, rhythmic, anti-phase oscillations were observed for both Bmal1:luc
and Per2:luc signals in U2OS and MCF7 (FFT-based test for rhythmicity [41], p< 0.05 for all
Per2:luc recordings across all treatments, all Bmal1:luc recordings for treatments with 50 μM
nobiletin, and 8 out of 12 Bmal1:luc recordings treated with DMSO and 5 μM nobiletin). How-
ever, in MDA-MB-231 cells, Bmal1 and Per2 reporters showed oscillations consistently only
with 50 μM nobiletin treatment. These findings are consistent with previous results showing
that MDA-MB-231 cells lack detectable rhythms while MCF7 are rhythmic [32]. The average
time series from MDA-MB-231 cells (Fig 1A and S4C Fig) clearly shows elevated/enhanced
raw bioluminescence for days 0–6 in the Bmal1 reporter, and for approximately days 0–2 for
the Per2 reporter for 50 μM, but not for vehicle or the 5 μM treatment. De-trending reveals
these deviations from the baseline and shows they are much larger for the 50 μM nobiletin
condition versus the others; hence, the peak-to-trough amplitude is increased in MDA-MB-
231 cells. We also confirmed that the treatment of cells with DMSO vehicle did not affect circa-
dian oscillations, in comparison with non-treated cells (S6 and S7 Figs).
We further evaluated the characteristics of data from U2OS and MCF7 cells (MDA-MB-
231 cells were omitted due to lack of rhythmic patterns and are discussed further below). Our
analyses show that nobiletin results in modestly increased circadian periods in both U2OS-
Bmal1:luc and U2OS-Per2:luc cells (Fig 2), with higher concentrations yielding greater effects
(randomization test for difference in means, Bonferroni-corrected p< 0.05). The changes to
damping rates and amplitudes were not statistically significant, with the exception that 5 μM
nobiletin treatment led to more damped Per2:luc oscillations. A repeated analysis with peak-
and trough-finding methods for estimating the period, amplitude, and damping rate led to the
PLOS ONE Circadian and anti-oncogenic effects of nobiletin
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same trends (S8–S11 Figs). For MCF7 cells, the trends in period, amplitude, or damping rate
estimates across treatments varied, depending on the method used to estimate the properties
(S8–S11 Figs).
Nobiletin affects rhythmicity of MDA-MB-231 cell lines
Previous work by our group has shown that even using real-time luminometry with Bmal1
and Per2 reporters, circadian oscillations remain undetectable (and arrhythmic) in MDA-MB-
231 cells [32]. We find that this largely remains the case, however, at the highest concentration
of nobiletin treatment (50 μM), rhythmicity was found to be enhanced in both Bmal1:luc and
Per2:luc cells. This was determined by applying an FFT-base test for rhythmicity [50] to
recordings after removing an exponential (Fig 3) or quadratic (S12 Fig) trend. The results var-
ied depending on the length of time-series considered, but recordings from cells treated with
50 μM nobiletin consistently scored rhythmic at a higher rate than all others. Visual inspection
of the de-trended time-series confirms that nobiletin enhances rhythmicity (S13–S16 Figs). To
assess whether nobiletin resulted in enhanced overall transcription of Bmal1 or Per2, we con-
ducted an RT-PCR experiment with MDA-MB-231, U2OS, and MCF7 cells (S17 Fig). We
found that no significant average changes occurred following nobiletin treatment across all of
the cell lines, which were not synchronized.
Fig 1. Nobiletin alters circadian dynamics in bone and breast cancer cell lines. Shown are (A) raw and (B) de-trended mean traces of
(left) Bmal1:luc and (right) Per2:luc in (top) U2OS, (middle) MCF7, and (bottom) MDA-MB-231 cells, as obtained using luminometry.
Each cell type was exposed to DMSO (vehicle), and 5 μM and 50 μM nobiletin conditions. The semi-transparent envelopes around the
lines indicate the standard error of the mean (SEM). In several instances, the SEM is too small to extend beyond the line. (B) Each trace
was de-trended by subtracting the mean of a 24-h sliding window and smoothed using the mean of a 3-h sliding window.
https://doi.org/10.1371/journal.pone.0236315.g001
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Effects of nobiletin on oncogenic characteristics vary by cell type
Previous studies showed that nobiletin inhibits the proliferation of U2OS, MCF7, and
MDA-MB-231 cells [21,23,26] and reduces their migration and invasion [22,23,26,30]. As
nobiletin has been posited to have therapeutic potential, we were interested in determining
whether its effects were similar or differed by cell line. First, we assessed changes to cellular
migration following nobiletin treatment via wound-healing/scratch assay (Fig 4). The same
concentrations were used as in our assessments of circadian rhythms. In U2OS and
MDA-MB-231 cells, migration decreased in samples treated with 50 μM nobiletin (p< 0.001
comparing longitudinal data with replicates, as in Storey et al, 2005) [51]. In MDA-MB-231
cells, there was a 29.5% relative difference in mean wound closure between t = 12 h and t = 22
h for nobiletin compared to vehicle-treated samples; the difference between samples was sligh-
ter at the conclusion of the experiment (t = 24 h). In contrast, the effect on U2OS cells was
more subtle, with a 20.9% difference in mean wound closure between t = 12 h and t = 22 h,
Fig 2. Effects of nobiletin on circadian periods, amplitudes, and damping rates in (left) U2OS and (right) MCF7
cell lines. Shown are the distributions of (A) period, (B) amplitude, and (C) damping rate parameters estimated from
fitting a damped cosine curve to each de-trended bioluminescence recording. Within each subfigure, color indicates
experimental condition, with results from Bmal1:luc shown on left and Per2:luc on the right (N = 12 per reporter per
condition). The mean and median values are indicated with a black asterisk and square, respectively. Statistical
significance was evaluated via a randomization test for difference in means with a Bonferroni correction (� p< 0.05, ��
p< 0.01, ��� p< 0.001).
https://doi.org/10.1371/journal.pone.0236315.g002
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although the effect was sustained through the final time-point. Nobiletin had no significant
effect on migration of MCF7 cells.
We used a colony formation assay to determine whether nobiletin could affect anchorage-
independent colony formation in a three-dimensional environment. In this experiment, we
evaluated both colony area and size. In U2OS cells, colony areas surprisingly increased relative
to the vehicle-treated controls, by 36% and 50% for 5 and 50 μM treatments, respectively (Fig
5A and S18 Fig). However, the numbers of colonies present did not change compared to the
vehicle-treated samples (Fig 5D). In MCF7 cells, nobiletin did not significantly alter the area
or number of colonies (Fig 5B and 5E and S18 Fig). The most substantial changes in colony
size were observed in MDA-MB-231 cells, whose areas decreased by 49% and 73% for 5 and
50 μM treatments, respectively, relative to the vehicle control (Fig 5C and S18 Fig). In both
cases, we also found increased colony numbers (Fig 5F). Decreased colony sizes may be
accompanied by increased numbers because it is possible that nobiletin prevents the aggrega-
tion of smaller colonies into larger ones, which can result in higher numbers of smaller colo-
nies but fewer larger ones [36].
Fig 3. Nobiletin alters the rhythmicity of MDA-MB-231 cells. Shown are the fractions of recordings classified as
rhythmic (p < 0.05 in FFT-based test), after removing an exponential trend, using time-series with increasing end
times. The fraction scored rhythmic depends on how much of the time-series is included in the analysis, but cells
treated with 50 μM nobiletin consistently scored as rhythmic more frequently than those treated with either DMSO or
5 μM. The only exception is Per2:luc recordings with the first 108 hours analyzed.
https://doi.org/10.1371/journal.pone.0236315.g003
Fig 4. Effects of nobiletin on cellular migration of bone and breast cancer cells. A wound healing/scratch assay was performed with (A) U2OS, (B) MCF7, and (C)
MDA-MB-231 cells. Nobiletin reduced cell migration in U2OS and MDA-MB-231 cell lines at 50 μM concentration. No substantial changes were observed in MCF7
cells. Error bars represent SEM. Statistical significance was evaluated via comparison of longitudinal data (��� p< 0.001). NT = non-treated; Vehicle = DMSO-only
control (0.2%).
https://doi.org/10.1371/journal.pone.0236315.g004
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Discussion
Nobiletin is a small molecule with a range of therapeutic effects whose influence on circadian
rhythms has recently been uncovered. While numerous studies have evaluated its efficacy in
various disease models, to our knowledge only one has assessed therapeutic and circadian
effects concomitantly, addressing metabolic syndrome [2]. Because nobiletin has been shown
to result in beneficial outcomes in multiple cancer types, we considered it important to study
whether a correlation may exist between its anti-oncogenic and circadian changes. Circadian
rhythm disruption has been found to be associated with cancers and their aggressiveness. As
examples, peripheral blood mononuclear cells (PBMCs) from healthy individuals had circa-
dian oscillations while chronic myeloid leukemia did not [52], low tumor grade MCF7 cells
had circadian rhythms while high tumor grade MDA-MB-231 cells were arrhythmic [32], and
in models of disease progression, circadian discrepancies were observed in both breast [37]
and colon carcinoma cells [53].
In this study, we assessed how nobiletin affects circadian and cancerous characteristics in
three different cell lines. We hypothesized that nobiletin’s effects on oncogenic features,
including motility and anchorage-independent colony formation, would be accompanied by
changes in circadian rhythms, and that their extents may be linked. We employed U2OS,
MCF7, and MDA-MB-231 cells; while the first two possess strong and weaker oscillations,
respectively, MDA-MB-231 cells had been previously found to be arrhythmic [32]. The appli-
cation of luciferase reporters to track circadian rhythms has been widely used
[2,3,28,31,32,37,54,55] on account of their ability to elucidate even subtle circadian oscillations
in a higher resolution manner [32,37,54]. Raw data is typically detrended to remove artificial
trends or baselines associated with readings; various methods have been applied, and this is a
generally accepted part of circadian rhythm analysis [55–58]. It also assists in visualization of
Fig 5. Nobiletin alters colony area and number for bone and breast cancer cells. Following colony formation assays, colony areas were evaluated for (A) U2OS, (B)
MCF7, and (C) MDA-MB-231 cells. Nobiletin increased colony areas of U2OS cells in a statistically significant manner, did not affect colony area in MCF7 cells, and
most substantially reduced colony areas in a dose-dependent manner in MDA-MB-231 cells. Colony numbers were not affected in (D) U2OS or (E) MCF7 cells, and
significantly altered by both treatments in (F) MDA-MB-231 cells. Error bars represent SEM. Statistical significance was evaluated via Student’s t-test with a Bonferroni
correction (� p< 0.05, �� p< 0.01, ��� p< 0.001, ���� p< 0.0001). NT = non-treated; Vehicle = DMSO-only control (0.2%), NS = not significant.
https://doi.org/10.1371/journal.pone.0236315.g005
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subtle oscillations that cannot be observed in raw data due to the large scale of signal damping
compared to the magnitude of the oscillation being observed [32,55–58]. Following treatment
with nobiletin, U2OS and MCF7 showed subtle circadian alterations and slight changes to cel-
lular characteristics. In contrast, the MDA-MB-231 responses included a clear enhancement of
circadian oscillations and significant reduction in cell migration and colony area.
Previous studies using clock knockout and normal MEF cells showed amplitude enhance-
ments upon nobiletin treatment [2,3]. These effects are hypothesized to be a result of the acti-
vation by nobiletin of RORα and RORγ, transcriptional activators of the Bmal1 gene. In our
work, U2OS-Bmal1:luc, and MDA-MB-231 Bmal1:luc and Per2:luc cell lines showed ampli-
tude enhancements, with rescue of rhythmicity in MDA-MB-231 cells. However, no amplitude
changes were observed in U2OS-Per2:luc cells and nobiletin subtly reduced circadian ampli-
tudes of both MCF7 Bmal1:luc and Per2:luc cell lines. Our raw data supports these findings,
with the exception of MCF7 Bmal1:luc, where bioluminescence was enhanced. Nobiletin’s
enhancement of circadian amplitude may vary depending on initial characteristics. For exam-
ple, significant amplitude enhancement was observed previously in MEFs where CLOCK was
knocked-out [2], while standard MEFs showed more minor effects [3]. It is possible that the
outcomes of nobiletin treatment are dependent on circadian (dys)function. We observed that
rhythmic U2OS and MCF7 cells showed subtle changes, while arrhythmic MDA-MB-231 cells
showed clear alterations with nobiletin. Those cell lines where the clock was clearly function-
ing benefitted less than the one where it was not.
In terms of period, prior work showed that nobiletin increases the period of PER2::Luc
MEFs [2,3], and mouse liver slices [3]. We observed similar but subtle effects in both Bmal1
and Per2 U2OS reporter cells. However, MCF7 cells had no significant changes in period. In
MDA-MB-231 cells, periods could not be determined for arrhythmic oscillations, but for
rhythmic oscillations periods were shown to be within the circadian range. Our data showed
different circadian effects between the two reporters associated with the same cell line to same
nobiletin treatments (e.g. the periods of U2OS-Bmal1:luc versus -Per2:luc and the periods and
amplitudes of MCF7-Bmal1:luc versus -Per2:luc cell lines). Such disparate responses from
reporters in the same cell type have been seen previously in U2OS and NIH 3T3 cell lines [59].
This could be a result of having each reporter in a separate cell line. Therefore, in the future,
tracking both Bmal1 and Per2 rhythms concomitantly using a dual-luciferase reporter system
will be helpful.
Nobiletin also affected oncogenic features of the cancer cells to varying extents. Sheet
migration is a process where cancer cells migrate in two dimensions during metastasis, and
can be assessed via wound healing assay [60]. Furthermore, normal cells rely on contacts
between cells and extra cellular matrix for cell growth and division, while more aggressive
ones can grow without it. The ability of this anchorage-independent cell proliferation can be
measured using a colony formation assay [61]. The colony counts and areas obtained from
this assay are quantitative values that can determine tumorigenicity of a cell line [62]. In this
study, we measured the ability of cancer cells to migrate and proliferate in an anchorage-inde-
pendent manner in three dimensions [61] using both of these methods. We saw significantly
reduced cell migration at the highest concentration of nobiletin treatment in U2OS and
MDA-MB-231 cells, but not in MCF7 cells.
Many of the pathways associated with nobiletin’s anti-migration and–proliferation activi-
ties in the three cell lines tested are connected to the circadian clock, or can be connected to its
ROR target. In prior evaluation of nobiletin’s circadian effects, the presence of functional
RORα and RORγ was required [2]. A previous study showed that nobiletin reduced cell migra-
tion (to a similar extent as herein) via downregulation of matrix metallopeptidases (MMPs)
and nuclear factor kappa B (NF-κB) protein levels in U2OS cells [26]. MMPs are repressed by
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the circadian protein PER [63], while NF-κB has been shown to be downregulated by ROR
[64]. Hence, ROR activation and enhanced clock activity may affect migration. Our data
shows that nobiletin also reduced MDA-MB-231 migration at the highest concentration tested;
a previous study (using a higher concentration, 200 μM) showed that nobiletin inhibits motil-
ity by affecting cluster of differentiation 36 (CD36), phospho-signal transducer and activator
of transcription 3 (pSTAT3), and NF-κB proteins [30]. STAT3 has shown circadian rhythms
in rat suprachiasmatic nuclei (SCN) [65,66], and it is possible that nobiletin affects its oscilla-
tions as well. In our study, nobiletin did not alter MCF7 cell migration at the highest concen-
tration tested (50 μM). However, previous studies showed that it reduced cell migration at
concentrations of 50 μM [22], 100 μM and 200 μM [23]. Multiple experiments showed that
nobiletin down-regulates CD36, STAT3, pSTAT3, MMPs, and NF-κB proteins, among others
in MCF7 cells [22,23,30].
Colony areas concomitantly increased and decreased with dose in U2OS and MDA-MB-
231 cells, respectively, while MCF7 was not affected. Previous studies showed that nobiletin-
treated breast cancer cells had reduced cell proliferation in largely two-dimensional assays
[21,24]. In one, nobiletin caused G1 cell cycle block in MCF7 cells at 75 μM and 100 μM con-
centrations [21], while in another it arrested MCF7 cells in the G0/G1 phases of the cell cycle
at 50 μM and decreased ERK activation and suppressed cyclin D1 expression [67]. Cyclin D1
is a key regulator of G0/G1 cell-cycle checkpoint, and is under circadian regulation by a PER1
protein complex [68]. Hence, circadian enhancement via nobiletin may be involved. Another
study using MCF7 and MDA-MB-231 cells also showed that nobiletin reduced cell prolifera-
tion in the concentration range of 50 μM-300 μM, and affected the proto-oncogene tyrosine-
protein kinase (SRC)/focal adhesion kinase (FAK)/STAT3 pathway [23]. To the best of our
knowledge, nobiletin has been evaluated only in terms of three-dimensional growth in MCF7
cells using a sphere formation assay, where significant reductions in size were observed at
200 μM [30]. We also found decreased colony areas at the highest concentration tested. Colony
formation assays in other cancer cell lines such as ACHN and Caki2, showed that nobiletin
dose-dependently reduced colony numbers at concentrations up to 120 μM [18], and colony
numbers of H460 non-small cell lung cancer cells at 50 μM [69].
Interestingly, in our study, we found that nobiletin yields different circadian and anti-can-
cer effects (specifically reduction of cell migration in two-dimensions and formation of
anchorage independent colonies), depending on cell line. Another significant difference
among these cells is the levels of nobiletin metabolizing protein, Cytochrome P450 (CYP),
present. CYP metabolizes naturally occurring flavonoids; the metabolized products often have
higher activities compared to parent compounds [21,69]. Nobiletin has been shown to be
metabolized via CYP1 [21,24]. While CYP1 protein levels in U2OS cells have not yet been
determined, MDA-MB-231s have higher CYP1 expression compared to MCF7 [70]. While the
IC50 of nobiletin has not been determined in MDA-MB-231 cells, in another triple negative
cell line where CYP1 was shown to be constitutively expressed, MDA-MB-468 [24], the IC50 of
nobiletin is 0.1 ± 0.04 μM [24]. In contrast, in MCF7 cells it is 44 μM [21]. In the future, it
would be useful to determine whether nobiletin’s metabolites are responsible for its activity,
and to directly compare its effects in these cell lines in parallel.
In our study, we found that nobiletin can both induce circadian rhythmicity and reduce the
oncogenic features of cell migration in a two-dimensional layer and formation of anchorage
independent colonies in MDA-MB-231 cells. While our work focused on in vitro assessments,
others have observed that inductions of rhythms via different means can also affect tumors in
in vivo models. One study used a cyclin-dependent kinase inhibiting small molecule, Seliciclib,
that induced rhythmic clock gene expression and reduced tumor growth in Glasgow osteosar-
coma tumors in mice [71]. Two others used established methods for inducing/synchronizing
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rhythms, and showed that they too could affect tumors in vivo. Kiessling et al showed that
induction of circadian rhythmicity via dexamethasone, forskolin or heat shock all slowed B16
and HCT-116 tumor growth in vivo, [45] while Li et al demonstrated that induction of
rhythms based on meal time reduced P03 pancreatic adenocarcinoma tumor weight in mice
[72].
We conclude that alteration to cancer cell circadian rhythms and oncogenic features via
nobiletin treatment depend on cell type. We have observed that cells with greater circadian
changes also have more substantial effects on cellular characteristics, and vice-versa. In the
future, it is highly merited to study whether there is a direct relationship between circadian
alterations (rescue/enhancement) and affecting oncogenic features in cancer cells. Further-
more, because the densities of cell populations used can also affect the extent(s) to which
effects are observed due to growth stage, cell-cell interactions, and metabolic status [73,74],
nobiletin should also be evaluated in cells with differing levels of confluence.
Supporting information
S1 Fig. Cell viability assay. (A) U2OS, (B) MDA-MB-231, and (C) MCF7 cells were treated
under conditions shown. Viability was determined using Alamar blue assay. No significant dif-
ferences were observed in nobiletin-treated samples compared to vehicle (0.2% DMSO) sam-
ples, with the exception of the 50 μM U2OS cells. Error bars represent standard deviations
across three biological replicates. Statistical significance was evaluated via two tailed Student’s
t-test (�� Bonferroni-corrected p<0.01). NT = non-treated.
(TIF)
S2 Fig. Effects of nobiletin on circadian dynamics in bone and breast cancer cell lines. Rep-
licates of the luminometry data shown in Fig 1 are presented here, for (left) Bmal1:luc and
(right) Per2:luc in (A) U2OS, (B) MCF7, and (C) MDA-MB-231 cells. Each cell line was
treated with vehicle (0.2% DMSO), and 5 μM and 50 μM nobiletin conditions. N = 12 repli-
cates were obtained for each treatment and cell line. Data were evaluated beginning from
t = 0.5 (day); each trace has been de-trended by subtracting the mean of a 24h sliding window
and smoothed using the mean of a 3-h sliding window, making the de-trended date begin at
t = 1 (days).
(TIF)
S3 Fig. Effects of nobiletin on circadian dynamics in bone and breast cancer cell lines. We
show the individual replicates depicted in S2 Fig, further separated by condition and date.
N = 4 replicates were obtained for each treatment and cell line, on each of three separate dates
(indicated in the legends). Data were evaluated beginning from t = 0.5 (day); each trace has
been de-trended by subtracting the mean of a 24h sliding window and smoothed using the
mean of a 3-h sliding window, making the de-trended date begin at t = 1 (days).
(TIF)
S4 Fig. Effects of nobiletin on circadian dynamics in bone and breast cancer cell lines.
Shown are the raw data for (left) Bmal1:luc and (right) Per2:luc traces in (A) U2OS, (B) MCF7,
and (C) MDA-MB-231 cells under vehicle (0.2% DMSO), and 5 μM and 50 μM nobiletin treat-
ment conditions. N = 12 replicates were obtained for each treatment and cell line.
(TIF)
S5 Fig. Effects of nobiletin on circadian dynamics in bone and breast cancer cell lines. We
show the individual replicates of raw data depicted in S4 Fig, further separated by condition
and date. N = 4 replicates were obtained for each treatment and cell line, on each of three
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separate dates (indicated in the legends).
(TIF)
S6 Fig. Vehicle treatment has no effect on circadian oscillations. Shown are the smoothed
and de-trended replicates for Bmal1:luc and Per2:luc reporters in (A) U2OS, (B) MCF7, and
(C) MDA-MB-231 cells under non-treated (black) and vehicle-treated (gray) conditions.
N = 4 for each treatment for each cell line. Data were evaluated beginning from t = 0.5 (day);
each trace has been de-trended by subtracting the mean of a 24 h sliding window and
smoothed using the mean of a 3 h sliding window, making the de-trended date begin at t = 1
(days).
(TIF)
S7 Fig. Vehicle treatment has no effect on circadian oscillations. Shown are raw data repli-
cates for Bmal1:luc and Per2:luc reporters in (A) U2OS, (B) MCF7, and (C) MDA-MB-231
cells under non-treated (black) and vehicle-treated (gray) conditions. N = 4 for each treatment
for each cell line.
(TIF)
S8 Fig. Multiple period-estimation methods reveal similar trends for U2OS Bmal1:luc and
Per2:luc and MCF7 Per2:luc recordings, but not MCF7 Bmal1:luc. Shown are the distribu-
tions of period estimates for each recording (N = 12 for each condition for each reporter and
cell line). For each cell line (U2OS on left, MCF7 on right) and each reporter (Bmal1 on left,
Per2 on right), we show the period distribution, color-coded by treatment (gray = vehicle,
blue = 5 μM nobiletin, light blue = 50 μM nobiletin). Each row shows results from a different
method (DC = damped cosine-fitting; the remaining method names indicate the phase marker
used to estimate the period, e.g. “peak” indicates the difference in time between the peak of
each cycle is used). Randomization tests for difference in means were performed to determine
if treatment led to statistically significant differences. P-values were corrected according to
Bonferroni’s method (� p< 0.05, �� p< 0.01, ��� p< 0.001). For U2OS (both reporters) and
MCF7 Per2:luc, the period estimates of 50 μM nobiletin treated recordings are either longer
than or not statistically significantly different from those treated with vehicle or 5 μM. For
MCF7 Bmal1:luc, however, two methods (trough-to-trough estimates and mean-crossing
while levels are rising) indicate that the 50 μM nobiletin treatment leads to shorter periods and
one (mean-crossing while levels are falling) indicates that it leads to longer periods.
(TIF)
S9 Fig. Multiple amplitude-estimation methods reveal few trends for Bmal1:luc, the same
trends for U2OS Per2:luc, and conflicting trends for MCF7 Per2:luc. Shown are the distribu-
tions of amplitude estimates for each recording (N = 12 for each condition for each cell line).
For each cell line (U2OS on left, MCF7 on right) and each reporter (Bmal1 on left, Per2 on
right), we show the amplitude distribution, color-coded by treatment (gray = vehicle,
blue = 5 μM nobiletin, light blue = 50 μM nobiletin). Each row shows results from a different
method (DC = damped cosine-fitting; Cycle1 = difference between magnitudes of first peak
and first trough; Cycle2 = difference between magnitudes of second peak and second trough).
Randomization tests for difference in means were performed to determine if treatment led to
statistically significant differences. P-values were corrected according to Bonferroni’s method
(� p< 0.05, �� p< 0.01, ��� p< 0.001). For U2OS Bmal1:luc, there are no trends. For U2OS
Per2:luc, 50 μM treatment led to a smaller amplitude. For MCF7 Bmal1:luc, only the amplitude
of the second cycle is different across treatments, with a 50 μM treatment leading to a higher
amplitude. For MCF7 Per2:luc, 50 μM treatment led to a smaller amplitude.
(TIF)
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S10 Fig. Multiple damping-estimation methods reveal moderate trends for both U2OS
Bmal1:luc and for MCF7. Shown are the distributions of damping estimates for each record-
ing (N = 12 for each condition for each cell line). For each cell line (U2OS on left, MCF7 on
right) and each reporter (Bmal1 on left, Per2 on right), we show the amplitude distribution,
color-coded by treatment (gray = vehicle, blue = 5 μM nobiletin, light blue = 50 μM nobiletin).
Each row shows results from a different method (DC Damping rate = damped cosine-fitting;
Amplitude Loss = 1 –Cycle2 Amplitude/Cycle1 Amplitude). Randomization tests for differ-
ence in means were performed to determine if treatment led to statistically significant differ-
ences. P-values were corrected according to Bonferroni’s method (� p< 0.05, �� p< 0.01, ���
p< 0.001). For U2OS Bmal1:luc and Per2:luc, 50 μM nobiletin treatment leads to increased
amplitude loss. For MCF7, 50 μM nobiletin treatment reduces damping (as determined both
by cosine-fitting and by measuring amplitude loss from cycle 1 to cycle 2).
(TIF)
S11 Fig. Agreement of period-estimation methods is consistent for U2OS and mildly
inconsistent for MCF7. For a given reporter and treatment, each of 12 replicates had its
period estimated by 5 methods (damped-sine fitting, peak-to-peak, trough-to-trough, mean-
crossing-to-mean-crossing on the rise, mean-crossing-to-mean-crossing on the fall). The coef-
ficient of variation (CV) across the 5 methods is computed. Shown are the distributions of
CVs for (A) U2OS and (B) MCF7 Bmal1:luc and Per2:luc recordings. Color indicates treat-
ment (gray = vehicle, blue = 5 μM nobiletin, light blue = 50 μM nobiletin). For U2OS, the CV
of period estimation is less than 4%. For MCF7 Bmal1:luc, vehicle treatment and 5 μM nobile-
tin period estimates vary more (the standard deviation is 10% of the mean).
(TIF)
S12 Fig. Nobiletin alters the rhythmicity of MDA-MB-231 cells. Shown are the fractions of
recordings classified as rhythmic (p< 0.05 in FFT-based test), after removing a quadratic
trend, using time-series with increasing end times. The fraction scoring as rhythmic depends
on the extent of the time-series included in the analysis, but cells treated with 50 μM nobiletin
consistently scored as rhythmic more frequently than those treated with either vehicle or
5 μM. The only exception is for Bmal1:luc recordings with the first 96 hours analyzed.
(TIF)
S13 Fig. Removing a quadratic trend from the first four days shows that nobiletin alters
the rhythmicity of MDA-MB-231 cells. (A) Shown are luminometry recordings after remov-
ing a quadratic trend from the first 96 hours of data. Subfigure placement and color indicate
treatment (top/gray = vehicle, middle/blue = 5 μM nobiletin, bottom/light blue = 50 μM nobi-
letin). (B) Shown are the fractions of recordings classified as rhythmic by an FFT-based test,
using increasing p-value cut-offs. For Bmal1:luc, both vehicle-treated and 50 μM nobiletin-
treated cells are scored as rhythmic, but visual inspection demonstrates that the rhythm is
most prominent for recordings from the 50 μM nobiletin treatment. For Per2:luc, visual
inspection and the fraction scored as rhythmic both indicate that rhythms are present in cells
treated with 50 μM nobiletin.
(TIF)
S14 Fig. Removing a quadratic trend from the first five days shows that nobiletin alters the
rhythmicity of MDA-MB-231 cells. (A) Shown are luminometry recordings after removing a
quadratic trend from the first 120 hours of data. Subfigure placement and color indicate treat-
ment (top/gray = vehicle, middle/blue = 5 μM nobiletin, bottom/light blue = 50 μM nobiletin).
(B) Shown are fractions of recordings classified as rhythmic by an FFT-based test, using
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increasing p-value cut-offs. Visual inspection and the fraction scored as rhythmic (when
p = 0.05) both indicate that rhythms are present in cells treated with 50 μM nobiletin. For
Per2:luc, this pattern is consistent, regardless of the size of the p-value. For Bmal1:luc, both
vehicle-treated and 50 μM nobiletin-treated cells scored as rhythmic, but visual inspection
demonstrates that the rhythm is most prominent for recordings from the 50 μM nobiletin
treatment. For Per2:luc, visual inspection and the fraction scored as rhythmic both indicate
that rhythms are present in cells treated with 50 μM nobiletin.
(TIF)
S15 Fig. Removing an exponential trend from the first four days shows that nobiletin alters
the rhythmicity of MDA-MB-231 cells. (A) Shown are luminometry recordings after remov-
ing an exponential trend from the first 96 hours of data. Subfigure placement and color indi-
cate treatment (top/gray = vehicle, middle/blue = 5 μM nobiletin, bottom/light blue = 50 μM
nobiletin). (B) Shown are fractions of recordings classified as rhythmic by an FFT-base test,
using increasing p-value cut-offs. For Bmal1:luc, both vehicle- and 50 μM nobiletin-treated
cells scored as rhythmic, but visual inspection demonstrates that the rhythm is most promi-
nent for recordings from the 50 μM nobiletin treatment. For Per2:luc, visual inspection and
the fraction scored as rhythmic both indicate that rhythms are present in cells treated with
50 μM nobiletin.
(TIF)
S16 Fig. Removing an exponential trend from the first five days shows that nobiletin alters
the rhythmicity of MDA-MB-231 cells. (A) Shown are luminometry recordings after remov-
ing an exponential trend from the first 120 hours of data. Subfigure placement and color indi-
cate treatment (top/gray = vehicle, middle/blue = 5 μM nobiletin, bottom/light blue = 50 μM
nobiletin). (B) Shown are the fractions of recordings classified as rhythmic by and FFT-base
test, using increasing p-value cut-offs. Visual inspection and the fraction scored as rhythmic
(when p = 0.05) both indicate that rhythms are present in cells treated with 50 μM nobiletin.
For Per2:luc, this pattern is consistent, regardless of the size of the p-value.
(TIF)
S17 Fig. Nobiletin does not increase Bmal1 or Per2 mRNA levels in U2OS, MCF7, or
MDA-MB-231 cells. mRNA levels were quantified using RT-PCR. No significant differences
were observed in nobiletin treated samples compared to vehicle treated samples in any of the
cell lines tested. Each treatment contained three biological replicates, with three technical rep-
licates each. Error bars represent SEM. Statistical significance was evaluated via two tailed t-
test in R ggpubr library under equal variance, and 0.95 confidence interval (� p< 0.05).
NT = non-treated; Vehicle = 0.2% DMSO.
(TIF)
S18 Fig. Representative images from colony formation assay. A single image for each treat-
ment and cell line is shown. Scale bars are 106 μm.
(TIF)
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